Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BGB-16673 versus investigator's choice in previously treated CLL/SLL
NL-OMON60985Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Apr 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of catadegbrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (4 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
catadegbrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON60985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60985.